IFNB1 and viral infectious disease: Given that HCoV NL63, SARS-CoV, and SARS-CoV-2 robustly block IFN-β production [19,20,21,22,23,24,25,26,27], delivery of exogenous IFN-β via an IFNβ-ACE2 targeting mechanism is predicted to obviate a primary immune evasion tactic of coronaviruses, thereby blocking viral infection and systemic dissemination.